Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base

Cell Rep. 2021 Apr 6;35(1):108937. doi: 10.1016/j.celrep.2021.108937.

Abstract

Soluble "SOSIP"-stabilized envelope (Env) trimers are promising HIV-vaccine immunogens. However, they induce high-titer responses against the glycan-free trimer base, which is occluded on native virions. To delineate the effect on base responses of priming with immunogens targeting the fusion peptide (FP) site of vulnerability, here, we quantify the prevalence of trimer-base antibody responses in 49 non-human primates immunized with various SOSIP-stabilized Env trimers and FP-carrier conjugates. Trimer-base responses account for ∼90% of the overall trimer response in animals immunized with trimer only, ∼70% in animals immunized with a cocktail of SOSIP trimer and FP conjugate, and ∼30% in animals primed with FP conjugates before trimer immunization. Notably, neutralization breadth in FP-conjugate-primed animals correlates inversely with trimer-base responses. Our data provide methods to quantify the prevalence of trimer-base responses and reveal that FP-conjugate priming, either alone or as part of a cocktail, can reduce the trimer-base response and improve the neutralization outcome.

Keywords: HIV vaccine; SOSIP; fusion peptide; immune response; immunization regimen; immunogen cocktail; nanoparticle immunogen; neutralization; prefusion-stabilized trimer; trimer base.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Neutralizing / immunology
  • Antibody Formation / immunology*
  • Female
  • HIV-1 / immunology*
  • Humans
  • Immunization
  • Immunoglobulin Fab Fragments / immunology
  • Macaca mulatta
  • Male
  • Models, Biological
  • Peptides / immunology*
  • Protein Multimerization*
  • Recombinant Fusion Proteins / metabolism*
  • env Gene Products, Human Immunodeficiency Virus / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Immunoglobulin Fab Fragments
  • Peptides
  • Recombinant Fusion Proteins
  • env Gene Products, Human Immunodeficiency Virus